In a small and preliminary clinical trial, Johns Hopkins researchers and their collaborators have shown that an experimental gene therapy that uses viruses to introduce a therapeutic gene into the eye is safe and that it may be effective in preserving the vision of people with wet age-related macular degeneration (AMD). AMD is a leading cause of vision loss in the U.S., affecting an estimated 1.6 million Americans.
The disease is marked by growth of abnormal blood vessels that leak fluid into the central portion of the retina called the macula, which we use for reading, driving and recognizing faces.
The study published on May 16 in The Lancet, reports an exciting new approach in which a virus, similar to the common cold, but altered in the lab so that it is unable to cause disease, is used as a carrier for a gene and is injected into the eye. The virus penetrates retinal cells and deposits a gene, which turns the cells into factories for productions of a therapeutic protein, called sFLT01.
The abnormal blood vessels that cause wet AMD grow because patients have increased production of vascular endothelial growth factor (VEGF) in their retinas. Current treatments require injections of proteins directly into the eye that bind and inactivate VEGF, reducing fluid in the macula and improving vision. However, the therapeutic proteins exit the eye over the course of a month, so patients with wet AMD usually need to return to the clinic for more injections every six to eight weeks in order to stave off vision loss. Eye specialists say the burden and discomfort of the regimen is responsible for many patients not getting injections as frequently as they need, causing vision loss.
Because viruses naturally penetrate cells and leave behind genetic material, the investigators designed their virus to target retinal cells and provide them with a gene that produces sFLT01. Thus, retinal cells become factories that produce the therapeutic protein — potentially eliminating the need to repeatedly inject it.
“This preliminary study is a small but promising step towards a new approach that will not only reduce doctor visits and the anxiety and discomfort associated with repeated injections in the eye, but may improve long-term outcomes because prolonged suppression of VEGF is needed to preserve vision, and that is difficult to achieve with repeated injections because life often gets in the way,” says Peter Campochiaro, M.D., the George S. and Dolores D. Eccles Professor of Ophthalmology at the Johns Hopkins University School of Medicine.
The phase 1 clinical trial involved 19 men and women, 50 years old or older with advanced wet AMD.
Participants were divided into five different groups that received increasing doses from 2X10^8 to 2X10^10 viral particles containing the therapeutic gene in 0.05 mL of fluid. Each group was examined by investigators for signs of adverse reactions for at least 4 weeks before administering a higher dose to the next group.
After the virus deposited the gene, the cells began secreting sFLT01 which bound to VEGF and prevented it from stimulating leakage and growth of abnormal blood vessels. The goal is for the retinal cells infected by the virus to produce enough sFLT01 to permanently stop the progression of AMD.
After monitoring the first three groups and finding no dose-limiting toxicity, the researchers administered the maximum dose to a group of ten participants and observed no serious side effects. “Even at the highest dose, the treatment was quite safe. We found there were almost no adverse reactions in our patients,” Campochiaro says.
For safety and ethical reasons, the study group was composed of people for whom standard approved treatments were highly unlikely to regain vision, meaning in part that only 11 of the 19 had the potential for fluid reduction. Of those eleven patients, four showed dramatic improvements. The amount of fluid in their eyes dropped from severe to almost nothing, just like what is observed with optimal standard treatment, Campochiaro says. In addition, two other participants showed a partial reduction in the amount of fluid in their eyes.
Five participants showed no reduction in fluid levels. Surprisingly, the researchers say, they found that all of the patients who did not show improvement had pre-existing antibodies to the AAV2 virus.
From that result, the researchers conclude that even if further studies affirm the safety and value of their gene therapy, it may have limitations for broad use. That’s because an estimated sixty percent of the U.S. population has been infection with adeno-associated virus, the family of viruses that AAV2 belongs to, and have built an immunity to it. The researchers believe that in these patients, the immune system destroyed the virus before it could insert the therapeutic gene. Campochiaro explains, “The numbers are small and simply show a correlation, so we don’t know if serum antibodies are definitely an impediment, but more work is needed to determine this.”
The Latest on: Wet age-related macular degeneration
- Novartis Looks To Challenge Regeneron's Turf: Who Will Win This War? on November 17, 2017 at 12:56 pm
Novartis' data in Wet Age-related macular degeneration in two phase 3 trials showed to be superior over Regeneron's Eylea. Improved clinical outcomes in reduced active disease and reduced retinal fluid in the eye may help give brolucizumab a marketing ... […]
- Viewpoints in Retina on November 14, 2017 at 1:54 pm
Does cataract surgery contribute to the progression of wet age-related macular degeneration? Experts And Viewpoints, January 2016 Anti-VEGF Therapy: Data on MI, Stroke, and Mortality Risk New research evaluates whether intravitreal anti-VEGF therapy ... […]
- Wet Macular Degeneration Market Will See Strong Expansion Through 2024 on November 7, 2017 at 10:05 pm
flag=T&rep_ .. Wet Macular Degeneration Market: Drivers and Restraints Macular degeneration occurs in people above 60 years of age whereas younger people are also at risk. According to study conducted by AMD (Age related Macular Degeneration) Alliance ... […]
- Ask a Doctor: Can lasers improve my macular degeneration? on November 6, 2017 at 11:48 pm
Q: Can lasers improve my macular degeneration? A: Various laser therapies have been used in the past for wet age related macular degeneration. Though these laser therapies had some modest benefit, laser therapy is not considered first line therapy for most ... […]
- Global Wet Age-Related Macular Degeneration Market and Competitive Landscape 2017 - Research and Markets on September 13, 2017 at 10:24 am
The "Global Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2017" report has been added to Research and Markets' offering. Global Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2017, provides comprehensive ... […]
- Wet Age Related Macular Degeneration AMD Worldwide Market Analysis 2017 and Forecast 2021 on August 2, 2017 at 1:02 am
There are two types of AMD: Dry and Wet. About 90 per cent of AMD cases are classified as dry AMD. Usually, AMD starts as a dry type and can develop in one or both eyes. The process is slow and can advance over the course of several years. About 10 percent ... […]
- Eylea Will Dominate The Wet Age-Related Macular Degeneration Market Until 2018, When Its Share Will Become Threatened By Emerging Products on July 19, 2017 at 6:25 am
BURLINGTON, Mass., July 19, 2017 /PRNewswire/ -- Decision Resources Group finds that over the next ten years, the market for late age-related macular degeneration (AMD) therapies will become fragmented as additional branded vascular endothelial growth ... […]
- Wet Macular Degeneration Market: Emerging Trends and New Technologies Research 2016-2024 on June 5, 2017 at 6:08 am
According to study conducted by AMD (Age related Macular Degeneration ... of old age population all over the world is creating the high rise demand in wet macular degeneration market. According to World Health Organization (WHO) report, percentage of ... […]
- One stem cell treatment stabilizes macular degeneration, another blinds 3 patients on March 15, 2017 at 2:15 pm
In Japan, wet age-related macular degeneration is the most common form, but in Caucasian populations, only about 10% of people with age-related macular degeneration gets that form. The "dry" form involves the macula breaking down without growth of blood ... […]
via Google News and Bing News